Dallas, TX – Since the landmark Diabetes Control & Complications Trial (DCCT) in the early 90's we've all known that average blood sugar levels and tight glycemic control are improved through frequent blood glucose testing and team management with a knowledgeable remote caregiver.

Unfortunately, today's blood glucose meters lack the connectivity to facilitate this remote teaming interaction. The result is millions of people left to manage their diabetes in isolation, especially the newly diagnosed. Even with all of the increased sales of diabetes testing supplies, blood sugar control and
physician adherence to established standards of care worldwide remain unacceptable by every diabetes organization worldwide including the American Diabetes Association, American Association of Clinical Endocrinologists, American Association of Diabetes Educators and the International Diabetes Federation.


Direct costs of diabetes care in the USA have more than doubled in recent years, according to the Centers for Disease Control & Prevention. “Without any practical means of enjoying the benefits of team management, costs from the current paradigm of test and forget self-care will bankrupt our global economy,” says Kevin McMahon, President & CEO of Diabetech. Clinical inefficiencies also stem from this lack of connectivity further driving up costs. Even the recently introduced continuous glucose monitoring devices are not capable of supporting communication with knowledgeable remote caregivers.

Diabetech offers a better answer to patients and the healthcare industry when it comes to an effective model for diabetes care including control for spiralling costs. Diabetech’s GlucoMON blood glucose connectivity device ensures glucose meter accuracy and automates the collection and analysis of blood glucose data for use in the team management of diabetes. People typically report drops in their average blood glucose (haemoglobin A1c) levels from 10% -30% when they use a GlucoMON and even more in some cases. Advanced technology simplifying the process is the key. As Stephen Ponder, MD CDE and Diabetech's Chief Medical Officer likes to say, 'Diabetech makes improvements to self-care and remote
patient interventions ridiculously easy'.

Representatives from health plans, self-insured employers and individual participants and their families involved in our various Institutional Review Board approved research trials have been providing feedback culminating in support for the development of a new commercial version of the GlucoMON upgraded for the global market. Based on interim clinical trial results from GlucoMON-enabled intervention programs, payers are already acknowledging a clear path to their Return On Investment (ROI); a pivotal metric that has been difficult for generalist disease management firms to demonstrate.

More Voices